Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
J. McDermott, Antonio Jimeno
págs. 7-20
Siltuximab: a new option for the management of Castleman's disease.
N. Barquero Casas
págs. 21-28
Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
D.N Neubauer
págs. 29-36
The year's new drugs & biologics, 2014: Part I.
Ann I. Graul, Elisabet Cruces, Mark Stringer
págs. 36-88
Pharmacovigilance Discussion Forum –The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015 – London, UK).
Dennis S.C. Lam
págs. 89-92
© 2001-2024 Fundación Dialnet · Todos los derechos reservados
Coordinado por: